Language skills in cypriot-greek speaking toddlers with specific language delay

The current investigation examined longitudinally the emergence of specific linguistic parameters in toddlers with and without late onset of expressive language. The central aim of this investigation was to compare the linguistic skills of typically developing and late-talking toddlers while: (a) observing patterns of linguistic development between the two groups on specific parameters and (b) examining the impact of early language delay on language-specific parameters and comparing these with cross-linguistic data. The subjects were 18 Cypriot-Greek speaking toddlers classified as late-talkers (LTs), and 18 age-matched counterparts with normal course of language development (NLDs). Participants were assessed at 28 months, 32 months, and 36 months, using various linguistic measures such as receptive and expressive vocabulary, mean length of utterance as measured in words (MLU-W), and phonetic production. Overall, the two groups exhibited parallel developmental profiles, with a language lag favoring the LT group as compared to the NLD counterpart. The results of this study highlight the negative effect of early language delay on later language skills, even up to age three years and lend support to the current literature regarding the universal linguistic picture of early and persistent language delay. Finally, the findings are discussed in view of the need for further research with a focus on more language sensitive tools in testing later language outcomes. © 2011 Koninklijke Brill NV, Leiden

Evaluation of S1RBD-Specific IgG Antibody Responses following COVID-19 Vaccination in Healthcare Professionals in Cyprus: A Comparative Look between the Vaccines of Pfizer-BioNTech and AstraZeneca

There is an ongoing effort to report data on SARS-CoV-2 antibodies in different individuals. Ninety-seven healthcare workers were enrolled in this study (Pfizer’s BNT162b2, n = 52; and AstraZeneca’s ChAdOx1-S, n = 45) and S1RBD-specific IgG antibodies were analyzed over time. Both vaccines induced S1RBD-specific antibodies after the second dose. A significant increase in S1RBD-specific IgG median levels 3 weeks following the second dose was detected (BNT162b2, 118.0 BAU/mL to 2018.0 BAU/mL; ChAdOx1-S, 38.1 BAU/mL to 182.1 BAU/mL). At 3 months post the second dose, a significant decrease in S1RBD-specific IgG median levels was also evident (BNT162b2, 415.6 BAU/mL, ChAdOx1-S, 84.7 BAU/mL). The elimination rate of these antibodies was faster in BNT162b2- rather than ChAdOx1-S- vaccinated individuals. A booster dose induced a significant increase in the S1RBD-specific IgG median levels (BNT162b2, 1823.0 BAU/mL; ChAdOx1-S, 656.8 BAU/mL). This study is the first of its kind to characterize S1RBD-specific IgG antibody responses in vaccinated healthcare workers in Cyprus. While the positivity for S1RBD-specific antibodies was maintained 3 months after the second vaccine dose, the level of these antibodies waned over the same period, indicating the importance of a booster vaccination. The results herein could complement the public health policies regarding the immunization schedule for COVID-19

Characterization of IgG Antibody Response against SARS-CoV-2 (COVID-19) in the Cypriot Population

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has hit its second year and continues to damage lives and livelihoods across the globe. There continues to be a global effort to present serological data on SARS-CoV-2 antibodies in different individuals. As such, this study aimed to characterize the seroprevalence of SARS-CoV-2 antibodies in the Cypriot population for the first time since the pandemic started. Our results show that a majority of people infected with SARS-CoV-2 developed IgG antibodies against the virus, whether anti-NP, anti-S1RBD, or both, at least 20 days after their infection. Additionally, the percentage of people with at least one antibody against SARS-CoV-2 in the group of volunteers deemed SARS-CoV-2 negative via RT-PCR or who remain untested/undetermined (14.43%) is comparable to other reported percentages worldwide, ranging anywhere from 0.2% to 24%. We postulate that these percentages reflect the underreporting of true infections in the population, and also show the steady increase of herd immunity. Additionally, we showed a significantly marked decrease in anti-NP IgG antibodies in contrast to relatively stable levels of anti-S1RBD IgG antibodies in previously infected individuals across time